| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
The primary target of 5-Hydroxylansoprazole is the gastric proton pump, specifically the H⁺/K⁺ ATPase enzyme in gastric parietal cells. This enzyme is responsible for the final step in gastric acid secretion. By inhibiting the proton pump, 5-Hydroxylansoprazole reduces the secretion of gastric acid into the stomach lumen. The compound is a metabolite of lansoprazole, and its activity contributes to the overall pharmacological effect of the parent drug. The target is the same as that of other PPIs, which are used to treat acid-related disorders.
|
|---|---|
| ln Vitro |
In vitro, 5-Hydroxylansoprazole exhibits proton pump inhibitory activity similar to that of its parent compound, lansoprazole. It inhibits the H⁺/K⁺ ATPase enzyme, thereby reducing gastric acid secretion. However, as a metabolite, its potency may differ from that of the parent drug. The compound is primarily used as a reference standard in analytical assays to measure lansoprazole metabolism and to study the pharmacokinetics of lansoprazole. Its in vitro activity is assessed using proton pump inhibition assays or by measuring acid production in gastric cell models.
|
| ln Vivo |
In vivo, 5-Hydroxylansoprazole is formed as a metabolite of lansoprazole in the plasma. It contributes to the overall pharmacological effect of lansoprazole by inhibiting the proton pump. The compound's in vivo activity is primarily studied in the context of lansoprazole pharmacokinetics and pharmacodynamics. It is used as a marker of CYP2C19 activity, as its formation is dependent on this enzyme. However, 5-Hydroxylansoprazole itself is not administered as a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme assays for 5-Hydroxylansoprazole typically involve measuring its inhibition of the gastric proton pump (H⁺/K⁺ ATPase). The enzyme is isolated from gastric mucosal membranes and incubated with the compound in the presence of ATP. The release of inorganic phosphate from ATP hydrolysis is measured as an indicator of enzyme activity. The compound's inhibitory activity is expressed as the IC50 for inhibition of the proton pump. These assays are used to compare the potency of lansoprazole and its metabolites.
|
| Cell Assay |
Cellular assays for 5-Hydroxylansoprazole are typically performed using gastric cell lines or isolated gastric glands that express the proton pump. Cells are treated with the compound, and acid production is measured using a pH-sensitive dye or by quantifying the accumulation of weak bases. The compound's ability to inhibit acid secretion is assessed by measuring the reduction in acid production compared to untreated controls. These assays are used to study the cellular pharmacology of lansoprazole and its metabolites.
|
| Animal Protocol |
In vivo animal studies with 5-Hydroxylansoprazole are not typically performed, as the compound is a metabolite rather than a primary therapeutic agent. However, animal studies with lansoprazole would measure the formation of 5-Hydroxylansoprazole as a pharmacokinetic endpoint. In such studies, animals are administered lansoprazole, and blood samples are collected at various time points to measure the concentrations of lansoprazole and its metabolites, including 5-Hydroxylansoprazole. The pharmacokinetic parameters of the metabolite are then calculated.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
5-Hydroxylansoprazole is a known metabolite of lansoprazole in the human body. As a metabolite of lansoprazole, the pharmacokinetic properties of 5-Hydroxylansoprazole are determined by the metabolism of the parent drug. It is formed in plasma by CYP2C19-mediated hydroxylation of lansoprazole. The compound has a molecular weight of 385.36. Its formation and elimination are dependent on the activity of CYP2C19, which exhibits genetic polymorphism. However, detailed pharmacokinetic parameters for the metabolite itself are not extensively reported. |
| Toxicity/Toxicokinetics |
The toxicity of 5-Hydroxylansoprazole is expected to be similar to that of its parent compound, lansoprazole, as it is a major metabolite. PPIs are generally well-tolerated, but long-term use has been associated with various adverse effects. However, specific toxicological data for 5-Hydroxylansoprazole itself are not reported in the available literature. The compound is classified as a research-use-only chemical and is not intended for human consumption.
|
| References |
|
| Additional Infomation |
5-Hydroxylansoprazole is a research-grade compound and an active metabolite of lansoprazole. It is not approved for clinical use as a therapeutic agent. Its primary applications are in pharmacokinetic studies of lansoprazole metabolism, as a reference standard for analytical method development, and as a tool for studying CYP2C19 activity. The compound is also used in studies of drug-drug interactions involving CYP2C19.
|
| Molecular Formula |
C16H14F3N3O3S
|
|---|---|
| Molecular Weight |
385.36
|
| Exact Mass |
385.071
|
| CAS # |
131926-98-2
|
| PubChem CID |
9800271
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
>155ºC (dec.)
|
| LogP |
4.086
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
511
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
IDCLTMRSSAXUNY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14F3N3O3S/c1-9-13(20-5-4-14(9)25-8-16(17,18)19)7-26(24)15-21-11-3-2-10(23)6-12(11)22-15/h2-6,23H,7-8H2,1H3,(H,21,22)
|
| Chemical Name |
1H-Benzimidazol-6-ol, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-
|
| Synonyms |
AG 1908 AG-1908 AG19085-Hydroxylansoprazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~324.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5950 mL | 12.9749 mL | 25.9498 mL | |
| 5 mM | 0.5190 mL | 2.5950 mL | 5.1900 mL | |
| 10 mM | 0.2595 mL | 1.2975 mL | 2.5950 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
